MedTrace Logo

Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit

NCT05360225 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2024-11-04

No results posted yet for this study

Summary

A Non-interventional Biomarker Study for the testing of DNA extracted from tumour tissue biopsy samples, using the therascreen® KRAS RGQ PCR Kit, from patients with Non-Small Cell Lung Cancer, screened in Clinical Study (Protocol No. 20190294).

Conditions

  • Non Small Cell Lung Cancer

Interventions

DIAGNOSTIC_TEST

therascreen® KRAS RGQ PCR Kit

The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • QIAGEN Gaithersburg, Inc

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-02
Primary Completion
2022-05-26
Completion
2022-05-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05360225 on ClinicalTrials.gov